Docetaxel – OS not influenced by age (TAX327)
0.2
0.4
0.6
0.8
1
1.2
1.4
ITT
Age < 65 years
Age ≥ 65 years
Age ≥ 75 years
Pain: no
Pain: yes
KPS ≥ 80
KPS ≤ 70
Hazard ratio in favour of:
Docetaxel Mitoxantrone
•
In men ≥75 years, docetaxel
q3w & q1w resulted in more
dose reductions and
discontinuations for adverse
events than mitoxantrone
•
BUT trend to better
improvement in QoL, tumour
response and survival with
docetaxel q3w
Tannock IF et al. N Engl J Med 2004;351:1502–12;. Horgan AM et al. J Geriatr Oncol. 2014;5:119-26
QoL: quality of life
SAEU.CAB.16.07.0040j
